Apitope News

Latest Press Releases

Apitope regains global rights to its novel treatment for multiple sclerosis from Merck KGaA, Darmstadt, Germany.

October 17, 2016

Chepstow, UK and Hasselt, Belgium: October 17 2016 − Apitope is a drug discovery and development company focused on highly selective therapies that reinstate immune tolerance and thereby treat the underlying cause of autoimmune, as well as allergic diseases. Today Apitope announces it has regained global rights to its compound, ATX-MS-1467, a potentially disease-modifying therapy…

Details

Apitope awarded venture capital deal of the year at Wales dealmakers awards 2016

September 30, 2016

Cardiff, UK and Hasselt, Belgium: 27th September 2016 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, is pleased to announce it has won the “Venture Capital Deal of the Year” Award at the Wales Dealmakers Awards 2016 for its €12 million fundraising in September 2015. The…

Details

Apitope to Present at Bio€quity Europe in May 2016

May 9, 2016

Cardiff, UK and Hasselt, Belgium: 9 May 2016 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces that Dr Keith Martin, CEO of Apitope, is scheduled to present at Bio€quity Europe on Tuesday, 10 May 2016 at 2.20 pm CET at the Scandic Hotel, Copenhagen,…

Details

Apitope wins prize for presentation at the European Association for Haemophilia and Associated Disorders

March 9, 2016

Apitope wins prize for presentation at the European Association for Haemophilia and Associated Disorders (EAHAD) conference in Malmo, 9th February 2016. Apitope’s research director, Dr Lotta Jansson presented “treatment of FVIII inhibitors by prevention of their formation using pan DR binding ATX-F98-117: preclinical efficacy in humanized transgenic mice.”

Details

Apitope Raises €12 Million in Series B Funding to Progress Treatments for Autoimmune Diseases

September 29, 2015

Cardiff, UK and Hasselt, Belgium: 29 September 2015 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces it has successfully raised €12 million in a Series B financing. The round was led by new investor Wales Life Sciences Fund. Current investors Vesalius Biocapital, LRM, PMV and Wyvern also participated in the round. Existing shareholders include the Wellcome Trust. Brenig Preest, Wales Life Sciences Fund, will join the Apitope board.

Details

Apitope Announces Completion of Enrolment in Phase IIA Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis

August 6, 2015

Bristol, UK and Hasselt, Belgium – 6th August 2015 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced that its partner, Merck Serono, has completed patient enrolment for the Phase IIa study of ATX-MS-1467 (also known as M2736), an investigational immune-tolerising agent. It is currently…

Details